MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer. Lee CH, Park SY, Lee JS, Kim DS, et al. Breast Cancer Res 2025;27:136.

Read + Share

Amedeo Smart

Independent Medical Education

Read + Share

Lee CH, Park SY, Lee JS, Kim DS, et al. MSN/STAT3 drives cancer stemness and chemoresistance via IL-6/LPAR1 ligand receptor complex in triple-negative breast cancer. Breast Cancer Res 2025;27:136.
PMID: 40696387